
Sign up to save your podcasts
Or


An HRS meeting recap, Impella failure, sacubitril/valsartan, the purpose of trials, and a major breakthrough in evidence generation are the topics discussed by John Mandrola, MD in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. HRS Meeting Recap
II. Impella in VT ablation
- First-in-human Experience with Impella 5.0/5.5 for High-Risk Patients with Advanced Heart Failure Undergoing VT Ablationhttps://www.jacc.org/doi/10.1016/j.jacc.2023.05.012
III. Sacubitril/Valsartan
ARNI Bests ARB to Reduce NT-proBNP in Stabilized Preserved-EF HF
https://www.medscape.com/viewarticle/992461
- Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure
https://www.jacc.org/doi/10.1016/j.jacc.2023.04.019
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
https://www.nejm.org/doi/full/10.1056/nejmoa1908655
- Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
https://doi.org/10.1093/eurheartj/ehad344
- Bogdan Tweet
https://twitter.com/bogdienache/status/1660356776204595201?s=20
IV. Big Change in Reporting of Medical Evidence – Elan Trial
- Early versus Later Anticoagulation for Stroke with Atrial Fibrillationhttps://www.nejm.org/doi/full/10.1056/NEJMoa2303048
- Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): Protocol for an international, multicentre, randomised-controlled, two-arm, open, assessor-blinded trial https://doi.org/10.1177/23969873221106043
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: [email protected]
By Medscape4.9
862862 ratings
An HRS meeting recap, Impella failure, sacubitril/valsartan, the purpose of trials, and a major breakthrough in evidence generation are the topics discussed by John Mandrola, MD in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. HRS Meeting Recap
II. Impella in VT ablation
- First-in-human Experience with Impella 5.0/5.5 for High-Risk Patients with Advanced Heart Failure Undergoing VT Ablationhttps://www.jacc.org/doi/10.1016/j.jacc.2023.05.012
III. Sacubitril/Valsartan
ARNI Bests ARB to Reduce NT-proBNP in Stabilized Preserved-EF HF
https://www.medscape.com/viewarticle/992461
- Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure
https://www.jacc.org/doi/10.1016/j.jacc.2023.04.019
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
https://www.nejm.org/doi/full/10.1056/nejmoa1908655
- Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
https://doi.org/10.1093/eurheartj/ehad344
- Bogdan Tweet
https://twitter.com/bogdienache/status/1660356776204595201?s=20
IV. Big Change in Reporting of Medical Evidence – Elan Trial
- Early versus Later Anticoagulation for Stroke with Atrial Fibrillationhttps://www.nejm.org/doi/full/10.1056/NEJMoa2303048
- Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): Protocol for an international, multicentre, randomised-controlled, two-arm, open, assessor-blinded trial https://doi.org/10.1177/23969873221106043
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: [email protected]

1,876 Listeners

319 Listeners

543 Listeners

708 Listeners

502 Listeners

167 Listeners

14 Listeners

16 Listeners

3,387 Listeners

138 Listeners

1,141 Listeners

65 Listeners

521 Listeners

367 Listeners

61 Listeners

25 Listeners

7 Listeners

258 Listeners

440 Listeners

272 Listeners